Resitu receives US 510(k) clearance

The whole team at Resitu is delighted to announce that we have received 510(k) clearance from the US Food and Drug Administration for our first breast biopsy device, RESL09.

Today is just the start of our mission to Rethink breast lesion management. Keep your eyes and ears open for more exciting news from Resitu!